CO2017011020A2 - Derivados de 6-morfolinil-2-pirazolil-9h-purina y su uso como inhibidores de fosfoinositol-3-cinasa (pi3k) - Google Patents
Derivados de 6-morfolinil-2-pirazolil-9h-purina y su uso como inhibidores de fosfoinositol-3-cinasa (pi3k)Info
- Publication number
- CO2017011020A2 CO2017011020A2 CONC2017/0011020A CO2017011020A CO2017011020A2 CO 2017011020 A2 CO2017011020 A2 CO 2017011020A2 CO 2017011020 A CO2017011020 A CO 2017011020A CO 2017011020 A2 CO2017011020 A2 CO 2017011020A2
- Authority
- CO
- Colombia
- Prior art keywords
- pi3k
- formula
- phosphoinositol
- morpholinyl
- pyrazolyl
- Prior art date
Links
- MNMPQAGCFDSMLL-UHFFFAOYSA-N N1(CCOCC1)C1=C2N=CNC2=NC(=N1)C1=NNC=C1 Chemical class N1(CCOCC1)C1=C2N=CNC2=NC(=N1)C1=NNC=C1 MNMPQAGCFDSMLL-UHFFFAOYSA-N 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 108091007960 PI3Ks Proteins 0.000 abstract 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 abstract 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 229910052805 deuterium Inorganic materials 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003217 pyrazoles Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a un derivado de pirazol de fórmula (I), una sal del mismo, un profármaco del mismo, un hidrato del mismo, estereoisómero del mismo o una forma de deuterio del mismo farmacéuticamente aceptable, en donde, n, Y, Ra, R1, R2, R3, R4, R5 y R6 son como se definen en la presente posteriormente en la especificación, una composición farmacéutica que comprende un compuesto de fórmula (I) como un ingrediente activo, métodos de producción, y métodos de uso del mismo. fórmula (I) Particularmente, la presente invención proporciona un compuesto de fórmula (I) como inhibidores de fosfatidilinositol-3-cinasa (PI3K), el cual puede ser usado para tratar o prevenir enfermedades y trastornos inflamatorios, autoinmunes, huérfanos e hiperporliferativos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN878DE2015 | 2015-03-30 | ||
| PCT/IB2016/051762 WO2016157074A1 (en) | 2015-03-30 | 2016-03-29 | 6-morpholinyl-2-pyrazolyl-9h-purine derivatives and their use as pi3k inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2017011020A2 true CO2017011020A2 (es) | 2018-01-16 |
Family
ID=55854760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2017/0011020A CO2017011020A2 (es) | 2015-03-30 | 2017-10-27 | Derivados de 6-morfolinil-2-pirazolil-9h-purina y su uso como inhibidores de fosfoinositol-3-cinasa (pi3k) |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US10174035B2 (es) |
| EP (1) | EP3277682B1 (es) |
| JP (1) | JP6669417B2 (es) |
| KR (1) | KR20170131444A (es) |
| CN (1) | CN107428756B (es) |
| AU (1) | AU2016242080B2 (es) |
| BR (1) | BR112017020818A2 (es) |
| CA (1) | CA2980517C (es) |
| CO (1) | CO2017011020A2 (es) |
| CY (1) | CY1122018T1 (es) |
| DK (1) | DK3277682T3 (es) |
| ES (1) | ES2733505T3 (es) |
| HK (1) | HK1250161B (es) |
| HR (1) | HRP20190998T1 (es) |
| HU (1) | HUE045192T2 (es) |
| IL (1) | IL254688B (es) |
| LT (1) | LT3277682T (es) |
| MX (1) | MX2017012390A (es) |
| MY (1) | MY185268A (es) |
| PH (1) | PH12017501750A1 (es) |
| PL (1) | PL3277682T3 (es) |
| PT (1) | PT3277682T (es) |
| RS (1) | RS59213B1 (es) |
| RU (1) | RU2710549C2 (es) |
| SG (1) | SG11201706509QA (es) |
| SI (1) | SI3277682T1 (es) |
| SM (1) | SMT201900405T1 (es) |
| TR (1) | TR201910941T4 (es) |
| TW (1) | TWI689508B (es) |
| WO (1) | WO2016157074A1 (es) |
| ZA (1) | ZA201705530B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10822336B2 (en) | 2016-09-29 | 2020-11-03 | Daiichi Sankyo Company, Limited | Crystals of [2-(1-methyl-1H-pyrazol-4-yl)-6(morpholin-4-yl)-9H-purin-8-yl][4-(morpholin-4-yl)piperidin-1-yl]methanone and pharmaceutically acceptable salt thereof |
| CN107163061A (zh) * | 2017-04-14 | 2017-09-15 | 江西科技师范大学 | 含吡唑啉结构的噻吩并嘧啶类化合物的制备及应用 |
| CN110963955A (zh) * | 2018-09-30 | 2020-04-07 | 南京富润凯德生物医药有限公司 | 一种单氟代螺环化合物的合成方法及其中间体 |
| CN111087336A (zh) * | 2018-10-24 | 2020-05-01 | 南京富润凯德生物医药有限公司 | 一种双氟代螺环化合物的合成方法及其中间体 |
| CN110577515B (zh) * | 2019-09-02 | 2022-05-17 | 南通大学 | 一种4-(氮杂环丁烷-3-基)-1-甲基哌嗪-2-酮二盐酸盐的合成方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4768265B2 (ja) | 2002-10-15 | 2011-09-07 | シンタ ファーマシューティカルズ コーポレーション | 新規化合物 |
| WO2005000404A2 (en) | 2003-05-29 | 2005-01-06 | Synta Pharmaceuticals, Corp. | Heterocyclic compounds for preventing and treating disorders associated with excessive bone loss |
| GB2431156A (en) | 2005-10-11 | 2007-04-18 | Piramed Ltd | 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase |
| PT2041139E (pt) | 2006-04-26 | 2012-01-13 | Hoffmann La Roche | Compostos farmacêuticos |
| CN101511840A (zh) * | 2006-04-26 | 2009-08-19 | 吉宁特有限公司 | 磷酸肌醇3-激酶抑制剂化合物及其使用方法 |
| US20080233127A1 (en) | 2007-03-21 | 2008-09-25 | Wyeth | Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors |
| WO2009034386A1 (en) | 2007-09-13 | 2009-03-19 | Astrazeneca Ab | Derivatives of adenine and 8-aza-adenine and uses thereof-796 |
| WO2009045174A1 (en) | 2007-10-05 | 2009-04-09 | S*Bio Pte Ltd | 2-morpholinylpurines as inhibitors of pi3k |
| KR101643237B1 (ko) | 2007-10-05 | 2016-07-27 | 베라스템, 인코포레이티드 | 피리미딘 치환된 퓨린 유도체 |
| CN101835779B (zh) | 2007-10-26 | 2014-01-29 | 霍夫曼-拉罗奇有限公司 | 作为pi3激酶抑制剂的嘌呤衍生物 |
| WO2009100406A2 (en) | 2008-02-07 | 2009-08-13 | Synta Pharmaceuticals Corp. | Topical formulations for the treatment of psoriasis |
| US8158624B2 (en) | 2008-05-30 | 2012-04-17 | Genetech, Inc. | Purine PI3K inhibitor compounds and methods of use |
| EP2307414A4 (en) | 2008-07-07 | 2011-10-26 | Xcovery Holding Co Llc | SELECTIVE INHIBITORS OF PI3 KINASE ISOFORMS |
| TWI378933B (en) | 2008-10-14 | 2012-12-11 | Daiichi Sankyo Co Ltd | Morpholinopurine derivatives |
| WO2010114494A1 (en) | 2009-04-03 | 2010-10-07 | S*Bio Pte Ltd | 8-substituted-2-morpholino purines for use as pi3k and/or mtor inhibitors in the treatment of proliferative disorders |
| CA2772371A1 (en) | 2009-05-27 | 2010-12-02 | F. Hoffmann-La Roche Ag | Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use |
| EP2435438A1 (en) * | 2009-05-27 | 2012-04-04 | Genentech, Inc. | Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use |
| BR112012011188A2 (pt) | 2009-11-12 | 2021-06-29 | F.Hoffmann - La Roche Ag | ''composto,composição farmacêutica e uso de um composto" |
| US8293736B2 (en) | 2010-07-14 | 2012-10-23 | F. Hoffmann La Roche Ag | Purine compounds selective for PI3K P110 delta, and methods of use |
| ES2612503T3 (es) | 2010-09-14 | 2017-05-17 | Exelixis, Inc. | Compuestos 9H-purina como inhibidores de PI3K-delta y métodos para su preparación |
| BR112013014914B8 (pt) | 2010-12-16 | 2020-08-04 | Hoffmann La Roche | composto, composição farmacêutica e uso de um composto |
| PL2670753T3 (pl) | 2011-01-31 | 2017-05-31 | Novartis Ag | Nowe pochodne heterocykliczne |
| CA2825028A1 (en) | 2011-02-09 | 2012-08-16 | F. Hoffman-La Roche Ag | Heterocyclic compounds as pi3 kinase inhibitors |
-
2016
- 2016-03-29 LT LTEP16718910.9T patent/LT3277682T/lt unknown
- 2016-03-29 AU AU2016242080A patent/AU2016242080B2/en not_active Ceased
- 2016-03-29 PL PL16718910T patent/PL3277682T3/pl unknown
- 2016-03-29 WO PCT/IB2016/051762 patent/WO2016157074A1/en not_active Ceased
- 2016-03-29 KR KR1020177026959A patent/KR20170131444A/ko not_active Withdrawn
- 2016-03-29 TW TW105109845A patent/TWI689508B/zh not_active IP Right Cessation
- 2016-03-29 EP EP16718910.9A patent/EP3277682B1/en active Active
- 2016-03-29 SM SM20190405T patent/SMT201900405T1/it unknown
- 2016-03-29 MY MYPI2017001151A patent/MY185268A/en unknown
- 2016-03-29 ES ES16718910T patent/ES2733505T3/es active Active
- 2016-03-29 HR HRP20190998TT patent/HRP20190998T1/hr unknown
- 2016-03-29 RS RSP20190941 patent/RS59213B1/sr unknown
- 2016-03-29 MX MX2017012390A patent/MX2017012390A/es active IP Right Grant
- 2016-03-29 PT PT16718910T patent/PT3277682T/pt unknown
- 2016-03-29 SI SI201630267T patent/SI3277682T1/sl unknown
- 2016-03-29 BR BR112017020818-0A patent/BR112017020818A2/pt not_active IP Right Cessation
- 2016-03-29 HK HK18109578.1A patent/HK1250161B/en not_active IP Right Cessation
- 2016-03-29 CA CA2980517A patent/CA2980517C/en not_active Expired - Fee Related
- 2016-03-29 JP JP2017545934A patent/JP6669417B2/ja not_active Expired - Fee Related
- 2016-03-29 RU RU2017134110A patent/RU2710549C2/ru active
- 2016-03-29 HU HUE16718910A patent/HUE045192T2/hu unknown
- 2016-03-29 US US15/560,466 patent/US10174035B2/en active Active
- 2016-03-29 DK DK16718910.9T patent/DK3277682T3/da active
- 2016-03-29 TR TR2019/10941T patent/TR201910941T4/tr unknown
- 2016-03-29 SG SG11201706509QA patent/SG11201706509QA/en unknown
- 2016-03-29 CN CN201680019892.7A patent/CN107428756B/zh not_active Expired - Fee Related
-
2017
- 2017-08-15 ZA ZA2017/05530A patent/ZA201705530B/en unknown
- 2017-09-25 IL IL254688A patent/IL254688B/en active IP Right Grant
- 2017-09-25 PH PH12017501750A patent/PH12017501750A1/en unknown
- 2017-10-27 CO CONC2017/0011020A patent/CO2017011020A2/es unknown
-
2019
- 2019-07-19 CY CY20191100773T patent/CY1122018T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018502125A1 (en) | Bipyrazole derivatives as jak inhibitors | |
| MX378315B (es) | Derivados de ácido biliar como agonistas de fxr/tgr5 y métodos para el uso de los mismos | |
| CR20150628A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| CL2017002994A1 (es) | Compuestos de naftiridina como inhibidores de la quinasa jak | |
| CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| CU20170154A7 (es) | Derivados de pirazol-3-il-amina sustituidos como inhibidores cdk | |
| MX2020012520A (es) | Macrociclos con grupos p2' heterociclicos como inhibidores del factor xia. | |
| MX2017000806A (es) | Derivados de 2-h-indazol como inhibidores de kinasas dependientes de ciclinas (cdk) y usos terapeuticos de los mismos. | |
| UY35972A (es) | Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos | |
| MX381313B (es) | Derivados de benzimidazol como moduladores de ror-gamma | |
| MX2016010519A (es) | Moleculas para administracion a celulas cancerosas mutantes ros1. | |
| EA201690223A1 (ru) | Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение | |
| MX370900B (es) | Derivados del isocromeno como inhibidores de las fosfoinositido-3 cinasas. | |
| CO2017011020A2 (es) | Derivados de 6-morfolinil-2-pirazolil-9h-purina y su uso como inhibidores de fosfoinositol-3-cinasa (pi3k) | |
| CO2017000011A2 (es) | Derivados de quinolizinona como inhibidores de pi3k | |
| MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. | |
| MX386902B (es) | Metodos para el tratamiento de trastornos cardiovasculares. | |
| CL2016002870A1 (es) | Derivados bicíclicos y composición farmacéutica que incluye los mismos | |
| MY192305A (en) | Bipyrazole derivatives as jak inhibitors |